BMJ:不同降糖药导致不同并发症的风险大不相同

2016-03-31 zhaozhou 译 MedSci原创

 糖尿病常常伴有多种并发症,病情恶化时常常会导致患者截肢、失明、肾损伤和高糖血症等,往往给病患和家属带来巨大的伤痛以及经济上的负担。为了评价二型糖尿病患者的截肢、失明、严重肾损伤、高糖血症和低糖血症与处方降糖药之间的联系,尤其是新近上市的药物格列汀和格列酮类降糖药物,研究人员开展了一项初级护理的开放队列研究。 在2007年4月1日到2015年1月31日间,共有469688名二型

糖尿病常常伴有多种并发症,病情恶化时多会导致患者截肢、失明、肾损伤和高糖血症等,往往给患者和家属带来巨大的伤痛以及经济上的负担。为了评价2型糖尿病患者的截肢、失明、严重肾损伤、高糖血症和低糖血症与处方降糖药之间的联系,尤其是新近上市的格列汀和格列酮类降糖药物,研究人员开展了一项初级护理的开放队列研究。

在2007年4月1日到2015年1月31日间,共有469688名2型糖尿病患者被列入这个队列进行研究。主要的检测指标为首次记录的截肢、失明、严重肾损伤、高糖血症和低糖血症的记录。使用Cox模型来估算风险比。21308人和32533人在随访期间分别服用了格列酮和格列汀类降糖药。

服用不用药物的2型糖尿病患者中,格列酮药物与失明风险的降低有关;格列汀药物和低血糖症风险降低有关。尽管单独使用格列汀药物或者格列酮药物的患者数量仍旧偏低,但是相对于单独使用甲福明的患者来说,这两种药物可以显著降低肾损伤。

通过此次研究,可以发现不同的降糖药物的使用分别和不同的并发症风险有关。临床用药应该根据患者体质进行选择。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1847949, encodeId=920f184e949ed, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 28 07:56:00 CST 2016, time=2016-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86123, encodeId=40c386123f8, content=????, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 17 12:17:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757702, encodeId=7c651e57702a2, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Feb 26 09:56:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270824, encodeId=208412e08242a, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 02 14:56:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75103, encodeId=bc3ae510331, content=学习了,很好,值得, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Apr 01 08:38:00 CST 2016, time=2016-04-01, status=1, ipAttribution=)]
    2016-11-28 gaoxiaoe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1847949, encodeId=920f184e949ed, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 28 07:56:00 CST 2016, time=2016-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86123, encodeId=40c386123f8, content=????, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 17 12:17:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757702, encodeId=7c651e57702a2, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Feb 26 09:56:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270824, encodeId=208412e08242a, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 02 14:56:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75103, encodeId=bc3ae510331, content=学习了,很好,值得, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Apr 01 08:38:00 CST 2016, time=2016-04-01, status=1, ipAttribution=)]
    2016-05-17 忠诚向上

    ????

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1847949, encodeId=920f184e949ed, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 28 07:56:00 CST 2016, time=2016-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86123, encodeId=40c386123f8, content=????, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 17 12:17:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757702, encodeId=7c651e57702a2, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Feb 26 09:56:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270824, encodeId=208412e08242a, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 02 14:56:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75103, encodeId=bc3ae510331, content=学习了,很好,值得, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Apr 01 08:38:00 CST 2016, time=2016-04-01, status=1, ipAttribution=)]
    2017-02-26 丁鹏鹏
  4. [GetPortalCommentsPageByObjectIdResponse(id=1847949, encodeId=920f184e949ed, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 28 07:56:00 CST 2016, time=2016-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86123, encodeId=40c386123f8, content=????, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 17 12:17:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757702, encodeId=7c651e57702a2, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Feb 26 09:56:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270824, encodeId=208412e08242a, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 02 14:56:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75103, encodeId=bc3ae510331, content=学习了,很好,值得, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Apr 01 08:38:00 CST 2016, time=2016-04-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1847949, encodeId=920f184e949ed, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 28 07:56:00 CST 2016, time=2016-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86123, encodeId=40c386123f8, content=????, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 17 12:17:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757702, encodeId=7c651e57702a2, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Feb 26 09:56:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270824, encodeId=208412e08242a, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 02 14:56:00 CST 2016, time=2016-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75103, encodeId=bc3ae510331, content=学习了,很好,值得, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Apr 01 08:38:00 CST 2016, time=2016-04-01, status=1, ipAttribution=)]
    2016-04-01 dhzzm

    学习了,很好,值得

    0

相关资讯

BMJ Open Diabetes Res Care:脂联素预测前驱糖尿病(POP-ABC)

近期发表在BMJ Open Diabetes Res Care的研究称,对于父母伴有2型糖尿病的健康白人和黑人,脂联素水平可作为他们前驱糖尿病强有力的风险标志物。田纳西大学健康科学中心的Samuel Dagogo-Jack博士和同事对151名白人和182名黑人(平均年龄44.2岁)进行了一项研究,评估基线脂联素水平与前驱糖尿病发生率的关系。研究数据显示,纳入研究时所有参与者脂联素水平为3.14 µ

J Clin Pharm Ther:芦荟也能控制血糖?

近期一项荟萃分析显示,芦荟可改善前驱糖尿病患者的空腹血糖(FPG),改善2型糖尿病患者的糖化血红蛋白(HbA1c)!该荟萃分析共纳入了8项随机临床试验,涉及470名患者,其中有6篇文献是比较芦荟和安慰剂,还有2篇文献是比较芦荟和未治疗患者间,对前驱糖尿病(3篇)或2型糖尿病(5篇)血糖控制的影响。文献中的芦荟制剂包括粉碎的芦荟叶、新鲜提取的芦荟汁、芦荟凝胶粉、芦荟提取物等,治疗时间为2-3个月,大

血清中ω-6多不饱和脂肪酸含量高可降低2型糖尿病风险

东芬兰大学的一项新的研究表明,高的血清ω-6多不饱和脂肪酸浓度能显著降低2型糖尿病风险。这项研究结果发表在《American Journal of Clinical Nutrition》上。 据推测,高ω-6多不饱和脂肪酸摄入量会增加多种慢性疾病的风险,因为这些脂肪酸被认为能促进低度炎症。然而,对人类的研究还不能估测ω-6脂肪酸高摄入量和炎症之间的关系。此外,ω-6脂

JCEM:吡格列酮预防糖尿病,可以停药吗(ACT NOW研究)?

ACT NOW研究分析结果显示,葡萄糖耐量降低(IGT)的成年人,一旦停止服用吡格列酮,其预防2型糖尿病的保护性作用会逐渐减少,最终与对照组发展为2型糖尿病的风险相似;不过吡格列酮组与对照组相比,糖尿病的累积发病率更低,正常葡萄糖耐量的人群比例更大。该项随机、双盲、安慰剂对照试验,纳入了290名IGT患者,研究人员将参与者随机分为吡格列酮组(n=152,男性有74名,平均年龄54岁)和安慰剂对照组

Plos one:摄入多不饱和脂肪可延缓糖尿病进展

新研究表明,饮食里使用多不饱和脂肪代替饱和脂肪,可减缓前驱糖尿病进展为2型糖尿病的速度。伦敦国王大学糖尿病和营养学部门的Nicola Guess博士说:“研究结果表明,前驱糖尿病患者将受益于增多的多不饱和脂肪的摄入量。”Guess和同事对15名血糖量正常的参与者、14名运动员、23名肥胖人群、10名前驱葡萄糖患者和11名2型糖尿病患者进行了研究,探究饮食中脂肪酸的摄入对空腹血糖和餐后2小时血糖水平

Diabetes:抗癌药物格列卫可治疗2型糖尿病

3月28日报道,最新的一项研究表明,一种抗癌药物可以降低小鼠体内的胰岛素水平,在减少高血糖和肥胖风险的同时没有引起任何严重的副作用。 据美国合众社报道,韩国科学家在发表于《糖尿病》(Diabetes)上的一篇文章中表示,抗癌药物格列卫(Gleevec)对胰岛素和血糖水平比较敏感,这一点比较类似噻唑烷二酮(thiazolidinediones)。 科学家们发现,如果从PPARy中去除磷酸